EGFR
EGFR (epidermal growth factor receptor) is a gene encoding a transmembrane receptor tyrosine kinase.
EGFR (epidermal growth factor receptor) is a gene encoding a transmembrane receptor tyrosine kinase. Through ligand-dependent receptor activation and phosphorylation, EGFR participates in intracellular signaling pathways that regulate cellular proliferation, survival, migration, and differentiation. Its biological activity is closely associated with downstream signaling involving pathways such as MAPK and AKT, and dysregulated EGFR signaling is relevant to cancer biology.
EGFR is both a disease biomarker and a therapeutic target. Activating EGFR mutations are particularly important in non-small-cell lung cancer, where they guide treatment with EGFR tyrosine-kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib, afatinib, icotinib, and newer agents such as furmonertinib and mefatinib. EGFR amplification, altered receptor signaling, and ligand-mediated activation have also been investigated in glioblastoma, colorectal cancer, breast and esophageal cancers, ovarian cancer, and other solid tumors. Antibody-based approaches, including panitumumab and EGFR-directed bispecific antibodies, extend EGFR targeting beyond small-molecule kinase inhibition.
Rebuilt from PubMed 9 Sept 2026 · no new papers today
Where the papers sit
74 papers study egfr directly. The themes below are drawn from those 74. 1 paradigm shift and 1 new direction follow.
-
EGFR-Mutant Lung Cancer : EGFR-mutant NSCLC treatment is moving beyond first-line TKI monotherapy toward newer inhibitors, post-progression combinations and strategies that delay drug tolerance. CNS activity, progression-free survival and resistance mechanisms recur, with ULK1 and immune combinations emerging as targets. 19 papers · 25.7%
-
In Silico Anticancer Drug Discovery : Computational screening uses network pharmacology, molecular docking and dynamics to nominate EGFR-, HER2- and VEGFR-2-directed compounds. Apoptosis and kinase inhibition recur as validation endpoints, but the work remains predominantly preclinical and hypothesis-generating. 17 papers · 23%
-
EGFR-Targeted Drug Development : Drug development ranges from EGFR-TKIs and degraders to antibody strategies and dual-target compounds across lung, colorectal, ovarian and other cancers. Early progression, apoptosis, cytotoxicity and anatomical differences in antibody efficacy recur, without a single clinical direction. 12 papers · 16.2%
-
ErbB Signaling in Carcinoma : ErbB-directed therapy is being paired with immunotherapy in recurrent head and neck squamous cancer, while mechanistic studies map ERBB2/3 signaling across carcinomas. Resistance to lenvatinib and receptor-linked invasion remain recurring clinical and biological problems. 5 papers · 6.8%
-
Others — Targeted Cancer Therapeutics : Antibody targeting, photoimmunotherapy and delivery platforms recur across glioblastoma and other solid-tumor models, alongside a separate myeloma comparison. The cluster is therefore a collection of translational therapeutic approaches rather than one biological program. 21 papers · 28.4%
EGFR-targeted kinase inhibition can activate or repurpose EGFR biology rather than simply suppress it
The study of oncogenic receptor-tyrosine-kinase fusions in cancer found that fusion proteins suppress transmembrane EGFR signaling by sequestering Grb2, while targeted therapy releases Grb2 and potentiates EGFR-dependent survival and drug tolerance 42574606Aug. The study of gefitinib-mediated endocytosis in glioblastoma found that the EGFR inhibitor induces massive, nonphysiological internalization of EGFR, which can be exploited to improve uptake of EGFR-targeting antibodies and aptamers 42390764Jul. Together, these findings replace the assumption that an EGFR kinase inhibitor has only an inhibitory effect on the receptor: EGFR-directed drugs can instead restore EGFR signaling or redirect the receptor into a drug-delivery pathway, changing how their therapeutic effects and resistance mechanisms must be interpreted.
EGFR is implicated as a nuclear receptor component in clear-cell renal cell carcinoma
The clear-cell renal cell carcinoma study found EGFR in both membrane and nuclear compartments, with nuclear EGFR expression exceeding membrane expression and heregulin stimulation inducing nuclear translocation of HER2 and related ErbB receptors in vitro 42674699Aug. This places EGFR outside the set’s predominant roles as a membrane signaling target, mutation-defined driver, or cell-surface antigen: EGFR is also presented as part of a nuclear ErbB receptor network associated with renal-carcinoma biology, opening a distinct direction for mechanistic and clinical investigation.
Recent Findings on EGFR
EGFR-Targeted Cancer Therapy: EGFR tyrosine kinase inhibition remains central to cancer treatment, while new quinazolinone, thiazole, and degrader chemotypes seek broader or more selective activity 42645656Aug42102697May42138807May. Patient-derived tumoroids showed greater sensitivity to an EGFR-targeted antibody-drug conjugate than to EGFR tyrosine kinase inhibitors, highlighting treatment-specific vulnerabilities 42616271Aug. Resistance studies implicate amphiregulin-mediated EGFR activation, PI3K-dependent EGFR/SHP2/SOS1 signaling, HER2-EGFR switching, and RTK-fusion effects on Grb2 sequestration 42393288Jul42095550May42115409May42574606Aug. EGFR-SHC1 fusion caused intrinsic resistance through simultaneous EGFR kinase-domain and SRC-mediated SHC1 activation, whereas combined afatinib and dasatinib produced tumor regression in a refractory patient 41874451Mar. Work is also extending EGFR targeting beyond conventional blockade through local consolidation in EGFR-mutant NSCLC, near-infrared photoimmunotherapy, and applications in pulmonary hypertension, wound repair, and neurodegeneration 42068892May42527083Jul42044779Apr42289263Jun42107267May.
EGFR-Mutant Lung Cancer: First-line treatment studies continue to compare EGFR tyrosine kinase inhibitors, with mefatinib improving progression-free survival over gefitinib and high-dose furmonertinib showing substantial intracranial activity in patients with CNS metastases 42586967Aug42379171Jun. Three-year adjuvant icotinib significantly prolonged disease-free survival after resection and chemotherapy, although overall survival was not significantly different from placebo 42660909Aug. After EGFR-TKI progression, ivonescimab plus chemotherapy improved progression-free survival and showed a smaller overall-survival advantage, while serious treatment-related adverse events were more frequent 42636833Aug. Resistance research identifies ULK1-dependent drug-tolerant persister cells, Rb pathway inactivation with squamous transformation, and acquired BRAF fusions as therapeutic challenges 42407241Jul42308331Jun42546514Aug. Molecular selection can remain difficult because HER2 amplification and EGFR L858R may coexist, whereas EGFRxCD16 bispecific antibodies and EGFR/JAK2/STAT3-directed compounds offer additional post-progression strategies 42681853Sep42397418Jul42044554Apr.
Computational Anticancer Drug Discovery: Molecular docking, molecular dynamics, network pharmacology, and ADMET prediction repeatedly guide EGFR-directed or dual EGFR/HER2/VEGFR-2 discovery, but most candidates remain preclinical 42558029Aug42217499May42054875Apr. Several studies paired favorable computational binding with EGFR kinase, cell-based, or apoptosis assays, including tryptophenolide, quinazolinone 2b, and quinoxaline compound 12 42595923Aug42217499May42054875Apr. Computational models increasingly optimize multiple objectives, with DF-S4 generating novel kinase-directed molecules and a Bayesian workflow modeling EGFR phosphorylation-site-specific protein-protein interactions 42489643Jul42427025Jul. Results do not uniformly support EGFR as a direct target: itraconazole showed unstable EGFR and GLI1 complexes despite stronger support for Smoothened, whereas other studies reported stable EGFR complexes or direct kinase inhibition 42470490Jul42595923Aug. The field is therefore moving toward experimentally tested, multitarget scaffolds and machine-learning-guided design rather than toward a defined clinical development path.
ErbB Signaling in Carcinoma: ErbB signaling shows tissue-specific relationships between receptor localization, partner receptors, and treatment response. Nuclear HER2/ErbB3 co-expression correlated with higher Fuhrman Nuclear Grade and advanced stage in clear cell renal cell carcinoma, while heregulin induced nuclear translocation of HER2 and ErbB3 42674699Aug. In esophageal squamous cell carcinoma, epigallocatechin gallate was investigated for reducing arecoline-induced migration and invasion through EGFR/AKT/P38 signaling, whereas ACSS2-mediated EGFR palmitoylation sustained lenvatinib resistance in hepatocellular carcinoma 42373249Jun42134048May. Head and neck squamous cell carcinoma studies are testing EGFR-directed antibody combinations, including amivantamab and ficerafusp alfa with pembrolizumab, with amivantamab producing a 42% objective response rate after checkpoint inhibitor and chemotherapy exposure 42218660May42102329May.
Antibody engineering and targeted delivery are expanding EGFR-directed platforms beyond conventional inhibitors. DyAb improved low-data antibody-affinity prediction, while implantable microdevices enabled spatial testing of EGFR-targeting CAR-T cells in glioblastoma xenografts 42665538Aug42664321Aug. Lysosome-targeting systems degraded EGFR with modular UPTAB or LAT1-mediated LA-LYTAC designs, and mirabody-IR700 produced EGFR-dependent photoimmunotherapy responses in xenografts 42138807May42545113Aug42526257Jul. Glioblastoma studies also combined EGFR-directed imaging, antibody or aptamer endocytosis, Auger electron-emitting nanoparticles, and exosome-liposome delivery, but gefitinib-enhanced conjugate delivery still required further in vivo optimization 42390764Jul42276782Jun42466899Jul. Clinical and translational results remain mixed: erlotinib plus bevacizumab showed modest activity in heavily pretreated EGFR-amplified tumors, whereas EGFR-targeted T-cell engagers retained activity against extracellular-domain escape variants 42298055Jun42152476May. Other papers place EGFR in broader biomarker or resistance networks involving sarcopenia, microplastic-induced miscarriage, esophageal adenocarcinoma, RET-positive lung adenocarcinoma, and multiple myeloma, underscoring the cluster’s lack of a single biological direction 42642681Aug42629697Aug42527418Jul41921856Apr41881954Mar.
Written from 74 PubMed abstracts, each one cited by PMID above. Published: 2026-08-30. Last written: 2026-09-09 by GPT. Drafted by language models from published abstracts; not medical advice.